Published in final edited form as:

J Med Chem. 2013 December 27; 56(24): 10033–10044. doi:10.1021/jm401370h.

Optimization of Antitumor Modulators of Pre-mRNA Splicing

Chandraiah Lagiseti^{1,†}, Gustavo Palacios^{1,†}, Tinopiwa Goronga¹, Burgess Freeman², William Caufield², and Thomas R. Webb^{1,§,*}

¹Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-2794

²Preclinical PK Shared Resource, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-2794

Abstract

The spliceosome regulates pre-mRNA splicing, which is a critical process in normal mammalian cells. Recently recurrent mutations in numerous spliceosomal proteins have been associated with a number of cancers. Previously natural product antitumor agents have been shown to interact with one of the proteins that is subject to recurrent mutations (SF3B1). We report the optimization of a class of tumor-selective spliceosome modulators, which demonstrate significant in vivo antitumor activity. This optimization culminated in the discovery of sudemycin D6, which shows potent cytotoxic activity in the melanoma line SK-MEL-2 (IC₅₀ = 39 nM) and other tumor lines, including: JeKo-1 (IC₅₀ = 26 nM), HeLa (IC₅₀ = 50 nM), and SK-N-AS (IC₅₀ = 81 nM). We also report improved processes for the synthesis of these compounds. Our work supports the idea that sudemycin D6 is worthy of further investigation as a novel preclinical anticancer agent with application in the treatment of numerous human cancers.

INTRODUCTION

In most eukaryotic cells the splicing of pre-mRNA is a critical process that is catalyzed and regulated by the spliceosome machinery.¹ The spliceosome is a complex of many proteins and RNA that includes five small nuclear ribonucleoproteins (snRNPs) (U1, U2, U4/U6 and U5) and more than 150 other associated proteins.^{2,3} The spliceosome catalyzes removal of non-coded introns from pre-mRNA and joins coded exons together to generate mature RNA and also controls the process of alternative splicing, which is an important mechanism for regulating cellular function.⁴ Two bacterial natural products FR901464 (FR)^{5–7} and pladienolide (PD)^{8,9} (see Figure 1) have been reported to target the SF3B subunit of the spliceosome.^{10,11} Subsequent to those initial discoveries the list of bacterial natural products targeting the SF3B subunit has grown (see Figure 1) to include other bacterial natural products including herboxidiene (GEX1A)¹² (isolated from *Streptomyces* sp. A7847), and the thailanstatins (isolated from *Burkholderia thailandensis*).¹³ A similar interaction with the SF3B subunit is also likely for the macrolide natural product FD-895, given its potent biological activity and its high structural and pharmacophore similarity to PD.^{14,15} These bacterial fermentation products show cytotoxic IC₅₀s in the low nanomolar range in several tumor cell lines and have been reported to have a similar distinctive effect on the cell cycle

§Address as of January 2014: SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025-3493. thomas.webb@sri.com.

*thomasr.webb@gmail.com

†These two authors contributed equally to this work

Supporting Information Available: Full experimental details for the in vitro and in vivo biological methods, all details for the synthesis of all new compounds, as well as the details for the single crystal X-ray structure of compound **5**. This material is available free of charge via the Internet at <http://pubs.acs.org>

in mammalian cell lines, including cell cycle arrest in the G1 and G2/M phases.^{5,16} Several of these natural products have also been reported to show potent antitumor activity in vitro and in vivo.¹⁷ Work in this area led to the development of the semisynthetic PD analog E7107 (see Figure 1) for clinical studies.¹¹

There is increasing evidence that aberrant splicing of pre-mRNA is a driver of tumorigenesis⁴ and that modulation of this process may be a valid target for cancer therapy.^{17,18,19,20} Subsequent to the characterization of FR and PD as spliceosome modulators, recurrent mutations in SF3B1 were independently identified in myelodysplastic syndromes (MDS),²¹ chronic lymphocytic leukemia (CLL),²² acute myeloid leukemia (AML)²³ and uveal melanoma.²⁴ The selective sensitivity of tumors to agents such as PD and meayamycin has been the topic of significant research efforts and has very recently been linked to overexpression of MYC,²⁵ or the perturbation of the pre-mRNA splicing of Mcl-1,²⁶ respectively. Thus the collective progress in natural product screening, target identification and high-throughput transcriptome sequencing has led to a remarkable convergence of independent research areas, which have simultaneously identified new oncology drug targets and new small-molecule therapeutic agents.^{17,20}

Numerous total synthetic approaches have been reported to FR, which is one of these active natural products. Most of these syntheses directly target the highly intricate natural product itself, or corresponding synthetically complex analogs.^{28–32} In spite of much progress it remains challenging to synthetically access large quantities of the natural product spliceosome modulators, or their close analogs, due to the structural complexity and the presence of 8 or more stereocenters.¹⁷ As part of our effort to develop a class of druglike and elegant natural product analogs we have previously reported the design and synthesis of FR analogs (the sudemycins)^{33–35} and pladienolide analogs,³⁶ which are active simplified compounds that effectively modulate alternate splicing.³⁵ Most of our related lead optimization work has focused on the sudemycins, which are chemically stable synthetic molecules that were designed based on the known FR structure-activity relationships (SAR) and the application of a hypothetical consensus pharmacophore model that is derived from molecular overlays of FR and PD.^{33–35}

Though the application of small molecule splicing modulators may have broad anticancer potential we chose to focus some significant attention on melanoma for the purposes of the present study, since melanoma is one of several cancers that continue to be a major therapeutic challenge in the field of pediatric and adult cancer chemotherapy.³⁷ We have previously reported the initial SAR with the early generations of these compounds, in addition to the initial results of in vitro evaluation of these analogs in a panel of tumor cell lines.^{33,34} This work led to the identification of several types of drug sensitive tumor lines, which included several melanoma lines. Because of this observed drug sensitivity, combined with the critical need for new therapeutic agents for melanoma, we have also emphasized in vivo experiments with melanoma. As such, melanoma as a model disease serves to exemplify a major potential clinical application for a sudemycin lead candidate. We now report progress in lead optimization efforts that have led to novel sudemycin analogs possessing in vivo activity in a murine melanoma xenograft model. Additionally, we also report the results from in vitro dual-agent synergy/antagonism experiments with these newly optimized sudemycin derivatives when combined with a set of approved and investigational antitumor drugs.

In the following we describe additional SAR results and new compounds that possess important structural modifications required for enhanced in vivo antitumor activity. In addition to substantial new data on the biological activity of these compounds, we also report new and substantially improved synthetic processes including the incorporation of a

novel sulfone reagent for the key Julia-Kocienski coupling step. The synthetic refinements allow for a much more efficient and scalable process that makes these sudemycin analogs available for clinical development.

RESULTS AND DISCUSSION

Synthesis

Previously we have reported the practical enantioselective and diastereospecific synthesis of key intermediates for the sudemycin series that includes a key Julia-Kocienski olefination (see Scheme 1 top panel).^{33,34} Our original synthetic scheme, though quite useful for the synthesis of new analogs, did not represent an efficient process for large amounts of sudemycin analogs for in vivo studies. We now report a much improved procedure (see Scheme 1 bottom panel and Scheme 2), using an alternate retrosynthetic dissection,³⁸ which makes use of the novel and highly crystalline sulfone (**5**). As can be seen in Scheme 1 this process gives a much higher overall yield of the key coupling product. As can also be seen in Scheme 2 the Julia-Kocienski reagent **5** can be readily derived from the previously reported spiroepoxy alcohol **8**.³³ Additional refinements to the synthesis of **5** include the replacement of hazardous NaH with the much more practical potassium t-butoxide for the generation of the sulfur ylide in the diastereospecific epoxidation step (to prepare **7**, see Experimental Section). We were also able to replace the hazardous pyrophoric reagent KH with potassium t-butoxide, as a refinement in the preparation of the intermediate (S,Z)-4-((tert-butyldimethylsilyl)oxy)pent-2-enoic acid used in this scheme (see Supporting Information).³³ A further enhancement in the synthetic process is the replacement of the diisobutyl aluminum hydride with the safer and more cost-effective polymethylhydrosiloxane (PMHS)/Ti(ⁱOPr)₄ combination³⁹ for the selective reduction of the ester to alcohol in the presence of spiroepoxide group (see Scheme 2). This new route also replaces the t-butoxycarbonyl protecting group with azide protection.^{40,41} (All synthetic protocols for these improvements are included in the experimental section and Supporting Information). These refinements allow for the practical synthesis of >10 gram amounts of sudemycin derivatives in a standard research laboratory setting, and will facilitate the development of synthetic processes suitable for larger scale synthesis that will be required for clinical studies.

Structure-activity Relationships (SAR)

Several factors must be optimized simultaneously in order to develop a lead compound that displays adequate tumor efficacy in vivo. These factors include: 1) potent on-target cell-based activity against the tumor, 2) reasonable metabolic stability (so that the drug will reach the tumor), 3) solubility (so that the drug can be formulated for in vivo delivery), and importantly 4) rapid onset of action (so that the drug acts before it is metabolized). The development of a compound that optimizes all of the parameters simultaneously is a significant challenge. In the case of our spliceosome-modulator lead optimization work we identified potency (as measured initially by cytotoxicity and confirmed by potent effects on the modulation of MDM2 splicing), druglike-solubility *and* rapid onset of cytotoxicity (as measured by drug washout experiments) as the primary initial qualities needed in a candidate drug molecule. Compounds were evaluated by initial screening in 72 h cytotoxicity against a small panel of tumor cell lines (generally JeKo1 and PC-3) and were selected for further evaluation on the basis of potency (IC₅₀ < 250 nM) in one of the cell lines of interest. Finally the best leads were ranked in order of the most promising solubility and metabolic stability characteristics. We have found the structure-activity of these spliceosome modulatory compounds to be very sensitive to even small changes in the general scaffolds (derivatives of **1** or **2**, shown in Figure 2). Our work^{33,34} and previously reported SAR work on analogs that have close structural similarity to FR, which has shown

pronounced limits on the activity tolerance for many structural changes.²⁷ In these cell-based assays biological activity can be affected by numerous factors: these include transport into the cell and into the nucleus (in order to reach the spliceosome), cellular metabolic stability, in addition to the affinity for the spliceosome. Therefore many of the modifications that we examined resulted in a significant reduction in cytotoxic activity, presumably by negatively impacting one of these important factors. These analogs were prepared using the previously published chemistry or that shown in Scheme 3.

Since FR and our first series of active compounds all contain a metabolically labile ester group we have previously investigated and reported the activity of the alcohol metabolites of our compounds, which were found to have cytotoxicity IC₅₀s values of >1 μ M against all cell lines examined,³⁵ consistent with the pharmacophore model that we have previously proposed.³³ Therefore we have now expanded on our previous reports via the synthesis and evaluation of new ester and optimized carbamate derivatives of the general structure shown in Figure 2 in order to identify potent compounds with improved solubility and improved metabolic stability.³⁴ As can be seen by inspection of Table 1, a new ester (**19a**) and a diverse collection of carbamate derivatives (**19b–19o**) were prepared and screened for cytotoxicity. In regard to the following SAR analysis, our focus was on the identification of potent compounds with IC₅₀s significantly below 1 μ M. Due to the inherent error in cytotoxicity measurements it is possible that some IC₅₀s may actually overlap. However, several general trends can be seen. For example though some level of substitution was possible, the compounds that contained longer chain groups (or polar solubilizing groups) were less potent than **1**. As can be seen by inspection of Table 1, together with our previously published work on carbamate derivatives of **18**,³⁴ there was limited tolerance for the length of the alkyl chains in groups used in the substitution of carbamate derivatives of these compounds. For example though the pivaloyl ester **19a** showed good activity, the n-butyl, diethyl and t-butyl carbamates (**19b**, **19c**, and **19d**, respectively) failed to show submicromolar activity in the two cell lines used in this screen, which represents a significant reduction in activity in the cytotoxicity screen (see Table 1, the SEM was less than $\pm 30\%$ in all cases and was determined as previously reported for the compounds in this table).³⁴ In the case of the SAR of N,N-dialkyl carbamates it was noted that the presence of a N-methyl group was better tolerated than other groups as can be seen with the N-methyl-N-propyl (**19e**), the N-methyl-N-butyl (**19g**) and other N-methyl-N-alkyl derivatives (**19h** and **19i**), when compared to **19b** or **19c**. Also it can be noted that cyclic carbamates (**19j–19m**) showed activity near 1 μ M so no significant improvement was seen with these cyclic compounds. The most active early esterase stable compound in this series was the dimethylamino carbamate derivative **1**, which we named sudemycin F1.³⁵ Based on this SAR data it could be hypothesized that a compact and relatively non-polar pocket near (or on) the SF3B subunit interaction site exists for the ester and carbamate functionalities, since activity goes down with both the length of hydrophobic groups and with increasing polarity (see Table 2), though other effects such as cellular uptake undoubtable influence activity as well.

We also explored the replacement of the carbonyloxy group that is present in the active carbamates and esters with other dual hydrogen-bond acceptor groups. If the key pharmacophore feature of the interaction of the carbonyloxy group is the presence of the dual 1,3 dihydrogen-bond acceptors then other functional groups might also fulfill this interaction and at the same time be fully resistant to esterase metabolism. To explore this hypothesis we prepared a set of compounds shown in Scheme 4. These heterocyclic derivatives could all be reasonable fits to the pharmacophore model, if simple hydrogen-bond dual acceptors are required, however none of these compounds showed cytotoxic IC₅₀s below 10 micromolar. This suggests that the steric requirements for this fit may be very constrained.

In addition we explored the importance of the NH group in these analogs; the pharmacophore model predicted the importance of the NH hydrogen-bond donor of the amide group and as predicted the N-methyl derivative of **19p** (**19q**, see supporting information) showed a complete abrogation of activity. These results taken together demonstrate the exquisite sensitivity of the spliceosome modulator pharmacophore, which is consistent with other published work.^{27,28} However, despite these constraints we were able to prepare a set of highly active compounds as summarized in Table 2 below.

In order to further explore the SAR we also prepared a set of exploratory compounds based on the less soluble series (containing the cyclohexyl ring rather than the 1,3-dioxane ring) to explore a set of conservative changes that could give active low-molecular weight analogs with better solubility properties (see Table 2). We were very pleasantly surprised to find that we had for the first time prepared compounds with improved cytotoxic activity, which also showed improved measured solubility properties. Most strikingly carbamate **3** showed low double-digit potency in contrast to the reduced activity seen in the monomethyl carbamate derivative **19n** when compared to **1**. We then did careful analysis of the top ranked lead compounds as shown in Table 2. Compound **3** has the best profile and stands out since it possesses potent cell-based activity combined with drug-like measured solubility (45 μ M in PBS). Compound **3** also showed potent cytotoxic activity in several other tumor lines investigated (see Supporting Information) including the melanoma line SK-MEL-2 (IC₅₀= 39 nM), as well as Hela (IC₅₀= 50 nM), SK-N-AS (IC₅₀= 81 nM) and PC-3 (IC₅₀= 142 nM).

Drug Synergy Studies

There is increasing evidence that certain synergistic anticancer drug combinations can be both more effective and less toxic than single-agent drug protocols.⁴² In consideration of this fact we next turned our attention to the *in vitro* anticancer drug combination properties of our splicing modulators in tumor cell lines by exploration of the combined dual agent cytotoxic effects of compounds **2** or **3** with successive members of a panel of 23 diverse types of clinically useful anticancer drugs and bioactive agents (see Table 3). While many of the combinations investigated (10 of the 23 agents) did not demonstrate either antagonism or synergy, we were able to uncover a number of drugs that show a significant combination effect in the first round of this screening efforts, using the 'First Drug Panel' shown in Table 3. While the identification of antagonistic or synergistic drug combinations remains an empirical process it is generally believed that agents that are antagonistic may both be targeting related signalling pathways and that agents that are synergistic are targeting distinct and complementary pathways.⁴² In principle it is also possible that an agent can also show synergy in other ways, for example by interfering with an important drug metabolic process and therefore stabilizing an agent that is a component of the combination therapy.

Subsequent to the first screen we focused our attention on agents showing synergy; the most notable of these was BEZ235, a dual inhibitor of phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR),⁴³ which is currently under investigation in numerous clinical trials. Given the strong synergy that we observed with BEZ235 we decided to investigate the combined effects of selective inhibitors of the two individual targets, i.e. PI3K and mTOR.⁴⁴ For this we chose PX-866 and temsirolimus which are selective inhibitors of PI3K and mTOR, respectively. Interestingly both of these agents showed synergy with lead compound **2**, though not as strong as that observed with the dual acting agent BEZ235 (see Table 3, Follow-up Drug Panel). As seen in Figure 3 this synergy is also seen with our best lead for both **2** and **3** in all cell lines investigated. The second strongest synergistic agent in the 'First Drug Panel' was the multi-kinase inhibitor sorafenib, which is also reported to have off-target inhibition of soluble epoxide hydrolase (sEH).⁴⁵ Some mammalian epoxide hydrolases are known to be important in the metabolism of

epoxide containing xenobiotics.⁴⁶ Since the sudemycins (and related drugs) have an epoxide group as a critical feature of their pharmacophore,³³ it is possible that this group is metabolized and inactivated by epoxide hydrolases present in tumor cells during the course of the cytotoxicity screening. We prepared the diol product of epoxide ring opening of compound **3** and found that this compound showed no detectable activity at a concentration of 10 micromolar (see Supporting Information, Scheme S4 and associated experimental procedures). Therefore we hypothesized that EH inhibitors may stabilize this class of drugs and so we explored the use of the EH inhibitor AUDA. As shown in Table 3 AUDA also demonstrates synergy with compound **2**, supporting the possibility that this epoxide metabolic pathway is significant for these drugs in vitro and potentially in vivo. It should be noted that since agents such as AUDA do not show cytotoxic effects the combination index (CI) can not be calculated for them. Of course these drug synergy studies are relevant for the design of potential future clinical studies that would include the use of relevant drug combinations of sudemycin D6.

In Vivo Tumor Xenograft Studies

Previously, our group reported the in vivo efficacy of the early lead, sudemycin C1,³⁵ which inhibited tumor growth in a lymphoma xenograft model when delivered intravenously.³⁴ Although the sudemycin C1-treated mice showed significant inhibition of tumor growth in this model (when compared to that of the vehicle-treated group) tumor proliferation was not completely inhibited. It is likely that the incomplete inhibition seen in our earlier study was a consequence of the short in vivo half-life of sudemycin C1. We propose that the observed short half-life is due to the presence of a labile ester group that is present in sudemycin C1, which we have previously shown to possess a metabolically labile ester group.³⁴ It is well known that esters are substrates for plasma and microsomal esterases that can rapidly metabolize esters to the corresponding alcohols, and this topic has recently been reviewed.⁴⁸ We have previously reported that hydrolysis of sudemycin C1 leads to an inactive alcohol (please see the Supporting Information for the assay protocol).³⁴ The other metabolically labile group that is required for activity in the sudemycins and the natural products²⁷ is the epoxide group, which can be a target for epoxide hydrolases, which would produce the inactivated diol metabolites.⁴⁶ This led us to conclude that it was necessary to deliver the drug via slow continuous jugular catheter (JVC) infusion in our in vivo efficacy studies.

Thus, following maximum tolerated dose (MTD) (data not shown) and pharmacokinetic studies (see Supporting Information under In vivo Pharmacokinetic Studies); we sought to determine the efficacy of the lead compound **3** in the inhibition of tumor growth in mice (Figure 4). Thus, SK-MEL-2 tumors were transplanted into male C.B-17 scid mice. The animals were subsequently infused over 4 hours with either vehicle (8 mice), or compound **3** (9 mice) for 5 consecutive days. No differences in fatalities or behavioral changes were observed between the control infusion and the drug treatment groups. In the drug treated group (50 mg/kg of compound **3** over 4 hours, once a day for 5 days) (Figure 4) we observed 100% inhibition of tumor growth during the infusion period and significant inhibition subsequent to this dosing period. When compound **3** was infused over a period of 4 hours it also induced moderate toxicity (as measured by weight loss); we observed an average maximum loss of weight of 12.7% ($\pm$ 2.3%, SEM) at 5 days of treatment. Nevertheless, the drug-treated group regained weight immediately after the cessation of the drug infusion and the animals returned to a normal weight range compared to the vehicle-infused mice by day 22 of the study. This demonstrates the single agent antitumor effects of the splicing modulator **3** in this xenograft model of an aggressive metastatic human melanoma.

CONCLUSIONS

The regulation of the pre-mRNA splicing process is abnormal in most cancers and numerous spliceosomal proteins are known to be recurrently mutated in a variety of tumors. We have optimized a class of totally synthetic natural product analogs targeting the spliceosome leading to sudemycin D6 (compound **3**) and further explored the SAR of this series. Sudemycin D6 shows potent cytotoxic activity in the melanoma line SK-MEL-2 (IC₅₀= 39 nM) as well as several other tumor lines that were investigated, including JeKo-1 (IC₅₀= 26 nM), HeLa (IC₅₀= 50 nM), SK-N-AS (IC₅₀= 81 nM) and PC-3 (IC₅₀= 142 nM). Sudemycin D6 also shows rapid and potent modulation of MDM2 alternate splicing in the Rh18 cell line as well as acceptable plasma stability, which led to its selection for in vivo studies. These in vivo studies demonstrate the activity of sudemycin D6 in a mouse melanoma xenograft model. In addition to this work we also report improved synthetic processes for this class of compounds (including **2** and **3**) as well as data from in vitro drug synergy studies using a panel of anticancer drugs. This work supports the idea that sudemycin D6 is worthy of further investigation as a novel preclinical anticancer agent, which may have application in the treatment of several types of human cancers.

Experimental Section

Biology General Aspects

Cell Culture—The cancer cell lines were purchased from the American Type Culture Collection (Manassas, VA), with the exception of the pediatric rhabdomyosarcoma Rh18, which was kindly provided by Dr. P. Houghton (Ohio State University – Nationwide Children’s Hospital, Columbus, OH). The following cell media were used: JeKo-1 (mantle cell lymphoma) cells were grown in RPMI 1640 medium containing 20% fetal bovine serum (FBS). PC-3 (prostate adenocarcinoma) cells were grown in Ham's F-12K with 10% FBS. HeLa (cervical adenocarcinoma), SK-MEL-2 (malignant melanoma), and WiDr (colorectal adenocarcinoma) cells were grown in EMEM medium containing 10% FBS. Neuroblastoma SK-N-AS cells were grown in RPMI 1640 medium containing 10% FBS. All cell culture media were supplemented with *L*-glutamine and penicillin/streptomycin. All cells were grown under standard conditions in CO₂ incubators, at 37 °C, with 5% CO₂, and 100% relative humidity.

In vitro Cytotoxicity Assays—The concentration of drug required to inhibit cell proliferation by 50% (IC₅₀) was determined as the percentage of viable cells remaining after a 72 h exposure to the drug. Adherent cells were seeded in 100 µL cell culture medium in 96-well plates. Depending on the cell proliferation rate, cells were seeded at 4,000 to 6,000 cells/well. Suspension cell cultures were initiated with 20,000 cells/well. The cells were incubated overnight at 37 °C, and then the drug treatments were started by adding 50 µL medium containing the corresponding drug dilution and DMSO. The final concentration of DMSO onto the cells was 0.5% v/v in all wells. The cells’ viability was determined using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI). The CellTiter-Glo reagent was prepared according to the manufacturer’s instructions, and then 50 µL reagent was added to each well for 1 h at rt. The luminescence was measured on an EnVision Multilabel Plate Reader (PerkinElmer, Waltham, MA). The IC₅₀ values were calculated from the dose-response curve analysis with GraphPad Prism 6.01 (GraphPad Software, La Jolla, CA) using the nonlinear regression model 4 Parameter Logistic. Nine concentrations were generated by 1:2 serial dilutions for each IC₅₀ assay. Each drug concentration was evaluated in triplicate or quadruplicate.

Drug Combination Assays—Preliminary cytotoxic screenings for each drug used in drug combination assays were performed to determine their cytotoxic dose range. The drug combination assays were initiated at a dose that was 4 or more times higher than the concentration of each drug required for the IC₅₀ value. Eight concentrations were established by 1:3 serial dilutions of the single drugs and their combinations with the splicing modulators. All drug concentrations were evaluated in triplicate in 96-well cell culture plates. Assays of individual drugs and drug combinations were run on the same tissue culture plate. Cell viability was determined using the CellTiter-Glo reagent. Drug interactions, in terms of synergism, additive effect, or antagonism, were based on the drugs' Combination Index (CI).⁴⁷

Combination Index for Constant-Ratio Drug Combinations—Luminescence data obtained from the cell viability determinations were formatted per the requirements of the analytical software (viability data range: >0 and <1). The formatted data were analyzed with the software CalcuSyn 2.1 (Biosoft, Cambridge, UK), which provides quantitative CI values for the drug interaction analyses (see ranges in Supplementary Table S2). All CI values were calculated at the combination dose that produced a cytotoxic effect in 50% of the cells (ED₅₀). AUDA does not show any cytotoxicity at any achievable concentration, so it was not possible to determine a CI for those drugs. Therefore, in these two cases the drug interaction was evaluated by comparing the IC₅₀ value of sudemycin standard (D1 or D6) with that of the IC₅₀ values resulting from the serial dilutions of the splicing modulator combined with a constant dose of the non-toxic drug.

Infusions in Tumor Bearing Mice—Xenograft tumors were first established from an SK-MEL-2 cell culture at the St. Jude Children's Research Hospital Xenograft Core. After these tumors were established as a mouse xenograft model, they were routinely maintained in the C.B-17 scid strain (Taconic Farms, Germantown, NY). Experimental animals were prepared by transplanting small pieces of dissected tumors from donor animals into recipient mice. All animal studies were performed in accordance with the St. Jude Children's Research Hospital Animal Care and Use Committee. SK-MEL-2 xenograft tumors were transplanted into male C.B-17 scid mice on Day -21. On Days -7 to -5, a jugular vein catheter was surgically implanted into each mouse. Beginning on Day 1, the animals (8 for vehicle, 9 for drug-treatment) received daily infusions of vehicle (10% 2-hydroxypropyl-β-cyclodextrin dissolved in 50 mM Na₂HPO₄/NaH₂PO₄, pH 7.4) or 50 mg/kg of the lead compound **3** for 5 consecutive days. Infusions were carried out by placing the animals inside a continuous infusion system (Instech Laboratories, Plymouth Meeting, PA), and delivering the vehicle or drug solution via the jugular catheter at a rate of 4 μL/min with a SP230iw syringe pump (WPI, Sarasota, FL). The total volume infused into the animals did not exceed 850 μL per day. Tumor size and animal weight were both continuously measured during and after infusion periods, 5 times per week (weekdays). Tumor volumes were determined based on the following equation: $Tu_{vol} = (\delta_1/2 + \delta_2/2)^{1.5708}$, where δ_1 and δ_2 are diameters measured with a caliper at right angles of each other. The size of the tumors ranged from 0.2 to 0.5 cm³ at the times the infusions were initiated.

Chemistry General Aspects

All materials and reagents were used as is unless otherwise indicated. Air- or moisture-sensitive reactions were carried out under a nitrogen atmosphere. THF, toluene, acetonitrile, *N,N*-dimethyl formamide and CH₂Cl₂ were distilled before use. All compounds were purified on Biotage pre-packed silica gel columns. TLC analysis was performed using glass TLC plates (0.25 mm, 60 F -254 silica gel). Visualization of the developed plates was accomplished by staining with ethanolic phosphomolybdic acid, ceric ammonium molybdate, or ethanolic ninhydrin followed by heating on a hot plate (120 °C). All

compounds for biological assays possessed a purity of >95% as determined by ultra-high pressure liquid chromatography on a Waters Acquity UPLC/PDA/ELSD/MS system carried out with a BEH C18 2.1 × 50 mm column using gradient elution with stationary phase: BEH C18, 1.7 mm, solvents: A: 0.1% formic acid in water, B: 0.1% formic acid in acetonitrile. NMR spectra were obtained on Bruker Avance II 400 MHz. The values d_H 7.26 and d_C 77.0 ppm were used as references for NMR spectroscopy in $CDCl_3$. The coupling constants deduced from 1H NMR data were obtained by first-order coupling analysis. Analytical and/or preparative SFC (Supercritical Fluid Chromatography) systems (AD-H) were used for analysis and purification of final chiral compounds. IR spectra were collected using a Nicolet IR 100 (FT IR). FT IR analyses were prepared neat or as neat films on KBr plates, and the data are reported in wave-numbers (cm^{-1}) unless specified otherwise. Melting points (mp) were obtained on a Buchi apparatus and are uncorrected. The University of Illinois Mass Spectroscopy Laboratories and High Throughput Analytical Center at St. Jude Children's Research Hospital collected the high resolution mass spectral data.

Chemistry Procedures

(S,Z)-5-(((2R,5R)-2-((2E,4E)-5-((3R,5S)-7,7-dimethyl-1,6-dioxaspiro[2.5]octan-5-yl)-3-methylpenta-2,4-dien-1-yl)-1,3-dioxan-5-yl)amino)-5-oxopent-3-en-2-yl dimethyl carbamate (1)—A stirred solution of (S,Z)-5-(((2R,5R)-2-((2E,4E)-5-((3R,5S)-7,7-dimethyl-1,6-dioxaspiro[2.5]octan-5-yl)-3-methylpenta-2,4-dien-1-yl)-1,3-dioxan-5-yl)amino)-5-oxopent-3-en-2-yl (4-nitrophenyl) carbonate (2.4 g, 4.09 mmol) in dichloroethane (35 mL) in an ice bath was treated with dimethyl amine (6.14 mL, 12.27 mmol, 2M in THF) dropwise. The resulting yellow solution was stirred at the same temperature for 10 min by which time LC/MS indicated that all starting material had been consumed. The solvent was then removed under reduced pressure. The yellow viscous crude residue was dissolved in a minimum volume of methylene chloride and treated with hexane. The resulting yellow solids were filtered and washed with 5% methylene chloride in hexane (25 mL). The filtrate was concentrated and purified on silica gel (100 g, 8–70% acetone in hexane) to give 1.72 g (86%) of carbamate as a fluffy solid. 1H NMR (400 MHz, $CDCl_3$) δ 7.93 (d, J = 8.2 Hz, 1H), 6.27 (d, J = 15.8 Hz, 1H), 5.91 – 5.84 (m, 1H), 5.84 – 5.78 (m, 2H), 5.58 (dd, J = 15.7, 6.6 Hz, 1H), 5.50 (t, J = 7.2 Hz, 1H), 4.58 (t, J = 5.3 Hz, 1H), 4.45 (ddd, J = 11.0, 6.6, 1.8 Hz, 1H), 4.06 – 3.87 (m, 5H), 2.89 (s, 6H), 2.58 – 2.54 (m, 2H), 2.54 – 2.47 (m, 2H), 2.03 – 1.86 (m, 2H), 1.73 (d, J = 0.9 Hz, 3H), 1.41 – 1.35 (m, 6H), 1.27 (s, 3H), 1.24 – 1.11 (m, 2H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 165.23, 156.30, 141.45, 135.70, 135.48, 127.86, 125.92, 123.67, 102.04, 73.04, 70.15, 70.12, 69.50, 69.39, 55.66, 51.05, 43.80, 42.45, 38.59, 36.31, 35.90, 34.20, 31.54, 23.77, 20.44, 12.59; HRMS (ESI) m/z Calcd for $C_{26}H_{40}N_2O_7Na$ (M+Na) $^+$ 515.2733, found 515.2734.

(S,Z)-5-(((1R,4R)-4-((2E,4E)-5-((3R,5S)-7,7-dimethyl-1,6-dioxaspiro[2.5]octan-5-yl)-3-methylpenta-2,4-dien-1-yl)cyclohexyl)amino)-5-oxopent-3-en-2-yl dimethylcarbamate (2)—A solution of activated carbonate **17** (1g, 1.7 mmol) in dichloroethane (15 mL) at 0 °C – was treated with dimethylamine (2.57 mL, 5.15 mmol, 2M in THF) dropwise. The resulting yellow solution was allowed to stir at 0 °C for 10 min by which time the TLC indicated that all of the starting material had been consumed. The solids formed (p-nitro phenol) in the reaction were filtered and washed with 5% methylene chloride in hexane (2×15 mL). The filtrate was concentrated and the resulting residue was purified on silica column (10–80% EtOAc in hexane) to give 755 mg (90%) of dimethyl carbamate derivative **2** as a fluffy solid. 1H NMR (400 MHz, $CDCl_3$) δ 8.23 (d, J = 8.0 Hz, 1H), 6.27 (d, J = 15.6 Hz, 1H), 5.82 (d, J = 11.4 Hz, 1H), 5.64 – 5.46 (m, 4H), 4.51 – 4.39 (m, 1H), 4.18 – 4.06 (m, 1H), 2.91 (s, 6H), 2.57 (s, 2H), 2.14 – 2.04 (td, J = 7.0, 4.6 Hz, 2H), 2.04 – 1.85 (m, 3H), 1.75–1.65 (m, 2H), 1.71 (s, 3H), 1.63 – 1.51 (m, 4H), 1.42 – 1.32 (s, 2H), 1.39 (s, 3H), 1.34 (d, J = 6.1 Hz, 3H), 1.28 (s, 3H), 1.24 – 1.10 (m, 2H); ^{13}C NMR

(101 MHz, CDCl₃) δ 165.15, 156.45, 136.36, 136.27, 133.60, 132.30, 126.85, 126.27, 73.02, 69.61, 69.53, 55.67, 51.03, 45.24, 42.45, 38.63, 36.66, 36.26, 35.89, 34.55, 31.53, 29.64, 29.50, 27.76, 27.43, 23.76, 20.66, 12.44; IR (Neat Film) 3267, 2874, 2804, 1656, 1635, 1511, 1370, 1172, 1038 cm⁻¹; HRMS (ESI) m/z Calcd for C₂₈H₄₅N₂O₅ (M+H)⁺ 489.3323, found 489.3334.

(S,Z)-5-(((1R,4R)-4-((2E,4E)-5-((3R,5S)-7,7-dimethyl-1,6-dioxaspiro[2.5]octan-5-yl)-3-methylpenta-2,4-dien-1-yl)cyclohexyl)amino)-5-oxopent-3-en-2-yl methylcarbamate (3)—A stirred solution of activated carbonate **17** (100 mg, 0.17 mmol) in 1,2 -dichloroethane (0.3 mL) was cooled in an ice bath and slowly treated with

methylamine (77 μ L, 0.51 mmol, 2M in THF). The resulting yellow solution was stirred at 0 °C for 10 min. The solid precipitate (p-nitro phenol) was removed by filtration and the residue was washed with a mixture of methylene chloride and hexane. The combined filtrates were concentrated and the residue was purified on a silica column (25g, 15–100% EtOAc in hexane) to give 75 mg (92%) of methyl carbamate **3** as a white viscous solid. ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, J = 7.7 Hz, 1H), 6.26 (d, J = 15.7 Hz, 1H), 5.82 (d, J = 10.8 Hz, 1H), 5.66 – 5.44 (m, 4H), 4.77 (s, 1H), 4.52 – 4.39 (m, 1H), 4.18 – 4.06 (m, 1H), 2.78 (d, J = 5.0 Hz, 3H), 2.57 (s, 2H), 2.09 (t, J = 7.1 Hz, 2H), 2.05 – 1.87 (m, 2H), 1.80 – 1.67 (m, 2H), 1.72 (s, 3H), 1.65 – 1.49 (m, 4H), 1.48–1.41 (m, 1H), 1.40 (s, 3H), 1.38 – 1.34 (m, 2H), 1.31 (d, J = 5.8 Hz, 3H), 1.28 (s, 3H), 1.24 – 1.12 (m, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 165.17, 157.03, 136.66, 136.16, 133.70, 132.10, 126.80, 126.06, 73.06, 69.52, 69.15, 55.68, 51.04, 45.36, 42.46, 38.57, 36.62, 34.42, 31.52, 29.57, 29.44, 27.68, 27.39, 27.33, 23.76, 20.60, 12.44; HRMS (ESI) m/z Calcd for C₂₇H₄₃N₂O₅ (M+H)⁺ 475.3172, found 475.3188.

2-(((3R,5S)-7,7-dimethyl-1,6-dioxaspiro[2.5]octan-5-yl)methyl)sulfonyl)benzo[d]thiazole (5)—A stirred solution of sulfide **9** (29 g, 90 mmol) in EtOH (700 mL) was cooled in an ice-bath and treated with a mixture of

ammonium molybdate 4H₂O (33.4 g, 27 mmol) and 30% H₂O₂ (123 mL, 1.08 mol) which had been adjusted to pH 4–5 with 7.0 phosphate buffer (49 mL, 0.26 M) at 0 °C, before the addition. The resulting suspension was allowed to stir for 14 h at rt. The reaction solution was divided into two portions for further work-up. Each portion was diluted with water (400 mL) and CH₂Cl₂ (400 mL) and the aqueous layer was extracted with CH₂Cl₂ (2×300 mL), and washed with brine (1×300 mL). The two organic portions were combined and dried over Na₂SO₄. The solvent was evaporated under reduced pressure to give the crude product as a white viscous solid. This was crystallized using methylene chloride and hexane to give 29 g (91%) of pure sulfone **5** as a white solid. Melting point = 124–126 °C; [α]_D²⁴ +4.5° (c = 1.1, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.25 – 8.17 (m, 1H), 8.04 -7.97 (m, 1H), 7.67 – 7.52 (m, 2H), 4.62 – 4.54 (m, 1H), 3.91 (dd, J = 14.8, 9.2 Hz, 1H), 3.43 (dd, J = 14.7, 2.8 Hz, 1H), 2.53 (dd, J = 17.9, 4.5 Hz, 2H), 1.96 – 1.74 (m, 2H), 1.25 (s, 3H), 1.23–1.20 (m, 1H), 1.01 (dd, J = 14.0, 1.8 Hz, 1H), 0.59 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 166.96, 152.69, 136.85, 127.80, 127.43, 125.40, 122.16, 73.53, 64.03, 60.14, 54.92, 50.80, 42.02, 37.02, 30.27, 22.90; IR (Neat Film) 2973, 2916, 1475, 1423, 1325, 1147, 1088, 1027 cm⁻¹; HRMS (ESI) m/z Calcd for C₁₆H₂₀NO₄S₂ (M+H)⁺ 354.0834, found 354.0843.

2-(((3R,5S)-7,7-dimethyl-1,6-dioxaspiro[2.5]octan-5-yl)methyl)thio)benzo[d]thiazole (9)—A solution of alcohol **8** (19.5 g, 113 mmol) in

THF (750 mL) was treated with Ph₃P (32.7 g, 6.31 mmol) and 2-mecapto benzothiazole (20.5 g, 119 mmol) and allowed to stir at rt. After 15 min, the reaction solution was cooled to 0 °C as a solution of diisopropyl azodicarboxylate (26 mL, 125 mmol) in toluene (70 mL) was added dropwise. The resulting yellow suspension was allowed to stir for 1h at 0 °C. The reaction mixture was then concentrated and the residue was triturated with 10% EtOAc in

hexane (500 mL). The solids were filtered and washed with 7.5% EtOAc in hexane (3×100 mL). The filtrate was then evaporated and the resulting residue was purified by flash chromatography (750 g, 5–30% EtOAc in hexane) to give 27.6 g (76%) of sulfide derivative **9** as a viscous oil. $[\alpha]_D^{24} +49.9^\circ$ ($c = 1.3$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.87 – 7.82 (m, 1H), 7.76 – 7.72 (m, 1H), 7.44 – 7.37 (m, 1H), 7.32 – 7.27 (m, 1H), 4.35 – 4.24 (m, 1H), 3.54 (ddd, $J = 19.8, 13.2, 5.8$ Hz, 2H), 2.57 (q, $J = 4.6$ Hz, 2H), 2.03 – 1.92 (m, 2H), 1.42 – 1.34 (m, 4H), 1.25 (s, 3H), 1.16 (dd, $J = 13.9, 1.9$ Hz, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 167.14, 153.17, 135.33, 125.98, 124.16, 121.46, 120.95, 73.58, 67.46, 55.56, 50.94, 42.42, 38.76, 37.04, 31.26, 23.72; IR (Neat Film) 2973, 2910, 1459, 1428, 1252, 1090, 1055, 1020 cm^{-1} ; HRMS (ESI) m/z Calcd for $\text{C}_{16}\text{H}_{20}\text{NO}_2\text{S}_2$ ($\text{M}+\text{H}$) $^+$ 322.0935, found 322.0930.

2-((1s,4s)-4-azidocyclohexyl)ethanol (11)—A stirred solution of alcohol **10** (10 g, 41.1 mmol) in methylene chloride (160 mL) was cooled in an ice-bath as trifluoroacetic acid (35.1 mL, 431 mmol) was slowly added. The resulting solution was allowed to warm to rt and stirred for an additional 4h. The solvent was then evaporated under reduced pressure and the resulting residue was dissolved in MeOH (200 mL), cooled in an ice-bath and then treated with solid K_2CO_3 (17.0 g, 123 mmol). This mixture was allowed to stir for 1h, filtered through a sintered funnel and washed with methylene chloride (2×50 mL). The combined filtrates were concentrated to give the free amine (5.8 g) as an oil. The crude amine was used in the next step without further purification.

A stirred solution of amine derivative (5.8 g, 40.5 mmol) in MeOH (225 mL) was sequentially treated with K_2CO_3 (12.5 g, 91 mmol) and $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.1 g, 0.4 mmol). The mixture was cooled in an ice-bath and 1H-imidazole-1-sulfonylazide HCl [**WARNING:** Subsequent to our development of this procedure this reagent (as the HCl salt) was shown to be an explosion hazard and safe alternatives have been discovered, which include the hydrogen sulfate salt. Because of this we do not recommend that the HCl salt be used in the future]^{41,49} (9.4 g, 54.7 mmol) was added portionwise to the resulting suspension. The reaction was warmed to rt and stirred overnight. The reaction mixture was then concentrated under vacuum and diluted with water (100 mL). The product was extracted with EtOAc (2×250 mL) and the combined organic layers were dried over Na_2SO_4 . This was concentrated and the resulting residue was purified on a silica column (160 g, 6–40% acetone in hexane) to give 5 g (73%) of the azide derivative **11**, as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 3.84 – 3.74 (m, 1H), 3.69 (t, $J = 6.1$ Hz, 2H), 1.88 – 1.72 (m, 2H), 1.66 – 1.43 (m, 8H), 1.40 – 1.18 (m, 2H); ^{13}C NMR (101 MHz, CDCl_3) δ 60.57, 57.92, 39.01, 32.67, 29.14, 27.45; IR (Neat Film) 3274, 2872, 2802, 2061, 1419, 1236, 1032 cm^{-1} ; HRMS (ESI) m/z Calcd for $\text{C}_8\text{H}_{16}\text{N}_3\text{O}$ ($\text{M}+\text{H}$) $^+$ 170.1288, found 170.1281.

(E)-ethyl 4-((1s,4s)-4-azidocyclohexyl)-2-methylbut-2-enoate (12)—A cold (–78 °C) stirred solution of oxalyl chloride (20.6 mL, 2M in methylene chloride, 41.4 mmol) in anhyd methylene chloride (80 mL) was treated with DMSO (4.2 mL, 59.1 mmol) dropwise. The resulting mixture was stirred for 15 min at –78 °C and treated with a solution of alcohol **11** (5 g, 29.5 mmol) in methylene chloride (60 mL). The resulting slurry was allowed to stir at –78 °C for 60 min and then treated with diisopropylethylamine (26.3 mL, 148 mmol). The cooling bath was removed, and the reaction mixture was allowed to stir at rt for 1 h to afford a yellow solution. This solution was then cooled in an ice-bath and then treated with ethyl 2-(triphenylphosphoranylidene)propanoate (16.0 g, 44.3mmol) with stirring for 10 min. The resulting stirred suspension was then allowed to warm to rt and allowed to stir overnight. Water (100 mL) and ether (300 mL) were then added to the reaction mixture. The organic layer was separated and washed sequentially with water (100 mL), brine (50 mL) and dried over Na_2SO_4 . This was concentrated and the resulting residue was purified on a silica

column (160 g, 2–20% EtOAc in hexane) to give 7g (94%) of conjugated ester **12** as an oil. ^1H NMR (400 MHz, CDCl_3) δ 6.75 (tq, $J = 7.7, 1.5$ Hz, 1H), 4.29 – 4.14 (q, $J = 7.1$ Hz, 2H), 3.86 – 3.72 (m, 1H), 2.11 (t, $J = 7.5$ Hz, 2H), 1.87 – 1.76 (m, 5H), 1.62 – 1.48 (m, 5H), 1.35 – 1.30 (m, 2H), 1.31 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 168.19, 140.43, 128.69, 60.45, 57.70, 36.43, 35.39, 29.22, 27.40, 14.30, 12.54; IR (Neat Film) 2874, 2804, 2061, 1677, 1236 cm^{-1} ; HRMS (ESI) m/z Calcd for $\text{C}_{13}\text{H}_{20}\text{N}_3\text{O}_2$ ($\text{M}-\text{H}$) $^+$ 250.1707, found 250.1716.

(E)-4-((1s,4s)-4-azidocyclohexyl)-2-methylbut-2-en-1-ol (13)—A solution of diisobutylaluminum hydride (66 mL, 1.0 M in hexanes) was added dropwise to a cold (-78°C) stirred solution of ester **12** in methylene chloride (150 mL). The resulting mixture was allowed to stir at -78°C for 2.5h. The reaction was quenched with MeOH (9 mL) and diluted with saturated sodium potassium tartrate tetrahydrate (150 mL) and EtOAc (160 mL). The resulting mixture was then allowed to stir vigorously for 2 h at rt to get a clear solution. The aqueous layer was extracted with EtOAc (2×200 mL) and the combined organic layers were dried over Na_2SO_4 . This was concentrated and the residue was purified on a silica column (160 g, 5–40% EtOAc in hexane) to give 5.3 g (91%) of pure alcohol **13** as an oil. ^1H NMR (400 MHz, CDCl_3) δ 5.41 (t, $J = 7.2$ Hz, 1H), 4.01 (s, 2H), 3.83 – 3.73 (m, 1H), 1.97 (t, $J = 6.9$ Hz, 2H), 1.85 – 1.75 (m, 4.3 Hz, 2H), 1.66 (s, 3H), 1.60 – 1.48 (m, 2H), 1.41 – 1.23 (m, 4H); ^{13}C NMR (101 MHz, CDCl_3) δ 135.69, 124.36, 68.96, 57.95, 36.85, 29.25, 27.32, 13.85; IR (Neat Film) 3275, 2870, 2801, 2060, 1418, 1236, 993 cm^{-1} ; HRMS (ESI) m/z Calcd for $\text{C}_{11}\text{H}_{19}\text{N}_3\text{ONa}$ ($\text{M}+\text{Na}$) $^+$ 232.1426, found 232.1423.

(E)-4-((1s,4s)-4-azidocyclohexyl)-2-methylbut-2-enal (14)—A solution of alcohol **13** (3.3 g, 15.7 mmol) and pyridine (12 mL) in anhyd methylene chloride (80 mL) at 0°C was treated with Dess-Martin periodinate (12.4 g, 23.6 mmol) portionwise. The resulting solution was stirred for 2 h at rt and added to a 1:1 mixture (300 mL) of saturated aqueous NaHCO_3 solution and saturated aqueous sodium thiosulfate solution. This mixture was allowed to stir for 30 min at rt. The aqueous layer was separated, extracted with EtOAc (2×400 mL) and the combined organic fractions were dried over Na_2SO_4 . This was concentrated and the resulting residue purified on silica column (2–20% EtOAc in hexane) to give 3.0 g (92%) of aldehyde **14** as an oil. ^1H NMR (400 MHz, CDCl_3) δ 9.41 (s, 1H), 6.50 (td, $J = 7.6, 1.0$ Hz, 1H), 3.88 – 3.78 (m, 1H), 2.30 (t, $J = 6.9$ Hz, 2H), 1.89 – 1.79 (m, 2H), 1.75 (d, $J = 0.4$ Hz, 3H), 1.64 – 1.51 (m, 5H), 1.44 – 1.29 (dt, $J = 14.5, 11.2$ Hz, 2H); ^{13}C NMR (101 MHz, CDCl_3) δ 195.16, 152.83, 140.31, 57.50, 36.46, 35.72, 29.22, 27.33, 9.41; IR (Neat Film) 2874, 2803, 2061, 1659, 1418, 1236 cm^{-1} ; HRMS (ESI) m/z Calcd for $\text{C}_{11}\text{H}_{18}\text{N}_3\text{O}$ ($\text{M}+\text{H}$) $^+$ 208.1445, found 208.1455.

(3R,7S)-7-((1E,3E)-5-((1s,4R)-4-azidocyclohexyl)-3-methylpenta-1,3-dien-1-yl)-5,5-dimethyl-1,6-dioxaspiro[2.5]octane (15)—A mixture of sulfone **5** (4.7 g, 13.4 mmol) and aldehyde **14** (2.4 g, 11.8 mmol) was concentrated with benzene (2×25 mL) under reduced pressure, dissolved in anhyd THF (80 mL), and cooled to -78°C . This stirred solution was treated dropwise with NaHMDS (14.7 mL, 1M in THF, 14.7 mmol) over 10 min. The resulting yellow suspension was stirred at -78°C for 1h, then allowed to warm in an ice-bath for 15 min, and then allowed to warm to rt and stirred for 0.5 h. The reaction mixture was quenched with pH 7 buffer solution (120 mL) and extracted with Et₂O (3×150 mL). The organic layer was dried (Na_2SO_4), filtered and concentrated *in vacuo*. The solids were removed by filtration after the addition of 10% CH_2Cl_2 in hexane. The resulting residue was purified on silica column (100 g, 2–20% EtOAc in hexane) to give 3.3 g (81%) of diene **15** (*E/Z* ratio 95:5) as an oil. ^1H NMR (400 MHz, CDCl_3) δ 6.26 (d, $J = 15.5$ Hz, 1H), 5.54 (dd, $J = 15.7, 6.7$ Hz, 1H), 5.46 (t, $J = 7.7$ Hz, 1H), 4.51 – 4.39 (m, 1H), 3.82 – 3.72 (m, 1H), 2.57 (s, 2H), 2.10 – 2.02 (m, 2H), 2.02 – 1.86 (m, 2H), 1.84 – 1.73 (m, 3H),

1.71 (s, 3H), 1.59 – 1.46 (m, 4H), 1.42 – 1.38 (s, 3H), 1.30 – 1.24 (m, 2H), 1.27 (s, 3H), 1.25 – 1.12 (m, 2H); ^{13}C NMR (101 MHz, CDCl_3) δ 136.19, 133.93, 131.74, 127.02, 73.01, 69.59, 57.94, 55.67, 51.03, 42.45, 38.62, 37.03, 34.88, 31.53, 29.24, 27.37, 27.32, 23.76, 12.50; IR (Neat Film) 2916, 2872, 2802, 2060, 1418, 1253, 956 cm^{-1} ; HRMS (ESI) m/z Calcd for $\text{C}_{20}\text{H}_{32}\text{N}_3\text{O}_2$ ($\text{M}+\text{H}$) $^+$ 346.2489, found 346.2492.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors wish to thank Peter Vogel, DVM, PhD. for the histopathologic evaluation of all tissues of animals subjected to infusions with Sudemycin D6 during the MTD study and Christopher L. Morton for the generation of the xenograft model and the tumor bearing animals used in this study. We would also like to thank John Bollinger, Ph.D. for his determination of the high resolution single crystal X-ray structure of compound **5** and Christopher Calabrese, Ph.D. for his help in the establishment of the infusion model in mice. We thank Lei Yang of the High Throughput Analytical Chemistry Center for the compound plasma stability and compound solubility results. We also thank Alan Pourpak, Xiaoli Cui and Dr. Steve Morris for the cytotoxicity data for the derivatives of compound **19**. This work was supported in part by NIH Grants CA140474 and by the American Lebanese Syrian Associated Charities and St. Jude Children's Research Hospital.

ABBREVIATIONS USED

FR	FR901464
PD	pladienolide
HBTU	<i>N,N,N',N'</i> -tetramethyl- <i>O</i> -(1 <i>H</i> -benzotriazol-1-yl)uronium hexafluorophosphate
NaHMDS	sodium bis(trimethylsilyl)amide
MeOH	methanol
EtOAc	ethyl acetate
AcOH	acetic acid
CI	combination index
CL	plasma clearance value
C_{max}	maximum plasma concentration
EH	epoxide hydrolase
FBS	fetal bovine serum
JVC	jugular vein catheter
LLOQ	lower limit of quantification
MLEM	maximum likelihood via the expectation maximization algorithm
RSE	relative standard error
SEM	standard error of the mean
snRNPs	small nuclear ribonucleic particles
T_{max}	time to reach C _{max}
Tu_{vol}	tumor volume

References

1. Kramer A. The structure and function of proteins involved in mammalian pre-mRNA splicing. *Annu. Rev. Biochem.* 1996; 65:367–409. [PubMed: 8811184]
2. Golas MM, Sander B, Will CL, Luhmann R, Stark H. Molecular architecture of the multiprotein splicing factor SF3b. *Science.* 2003; 300:980–984. [PubMed: 12738865]
3. Staley JP, Guthrie C. Mechanical devices of the spliceosome: motors, clocks, springs, and things. *Cell.* 1998; 92:315–326. [PubMed: 9476892]
4. Germann S, Gratadou L, Dutertre M, Auboeuf D. Splicing programs and cancer. *J. Nucleic Acids.* 2012; 2012:269570. [PubMed: 22132318]
5. Nakajima H, Hori Y, Terano H, Okuhara M, Manda T, Matsumoto S, Shimomura K. New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. *J. Antibiot. (Tokyo).* 1996; 49:1204–1211. [PubMed: 9031665]
6. Nakajima H, Sato B, Fujita T, Takase S, Terano H, Okuhara M. New antitumor substances, FR901463, FR901464 and FR901465. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. *J. Antibiot. (Tokyo).* 1996; 49:1196–1203. [PubMed: 9031664]
7. Nakajima H, Takase S, Terano H, Tanaka H. New antitumor substances, FR901463, FR901464 and FR901465. III. Structures of FR901463, FR901464 and FR901465. *J. Antibiot. (Tokyo).* 1997; 50:96–99. [PubMed: 9066774]
8. Mizui Y, Sakai T, Iwata M, Uenaka T, Okamoto K, Shimizu H, Yamori T, Yoshimatsu K, Asada M. Pladienolides, new substances from culture of *Streptomyces platensis* Mer-11107. III. In vitro and in vivo antitumor activities. *J. Antibiot. (Tokyo).* 2004; 57:188–196. [PubMed: 15152804]
9. Asai N, Kotake Y, Nijima J, Fukuda Y, Uehara T, Sakai T. Stereochemistry of pladienolide B. *J. Antibiot. (Tokyo).* 2007; 60:364–369. [PubMed: 17617693]
10. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, Watanabe H, Kitahara T, Yoshida T, Nakajima H, Tani T, Horinouchi S, Yoshida M. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. *Nat. Chem. Biol.* 2007; 3:576–583. [PubMed: 17643111]
11. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, Ishihama Y, Iwata M, Mizui Y. Splicing factor SF3b as a target of the antitumor natural product pladienolide. *Nat. Chem. Biol.* 2007; 3:570–575. [PubMed: 17643112]
12. Hasegawa M, Miura T, Kuzuya K, Inoue A, Won Ki S, Horinouchi S, Yoshida T, Kunoh T, Koseki K, Mino K, Sasaki R, Yoshida M, Mizukami T. Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product. *ACS Chem. Biol.* 2011; 6:229–233. [PubMed: 21138297]
13. Liu X, Biswas S, Berg MG, Antapli CM, Xie F, Wang Q, Tang MC, Tang GL, Zhang L, Dreyfuss G, Cheng YQ. Genomics-Guided Discovery of Thailanstatins A, B, and C As Pre-mRNA Splicing Inhibitors and Antiproliferative Agents from *Burkholderia thailandensis* MSMB43. *J. Nat. Prod.* 2013; 76:685–693. [PubMed: 23517093]
14. Mandel AL, Jones BD, La Clair JJ, Burkart MD. A synthetic entry to pladienolide B and FD-895. *Bioorg. Med. Chem. Lett.* 2007; 17:5159–5164. [PubMed: 17681759]
15. Villa R, Mandel AL, Jones BD, La Clair JJ, Burkart MD. Structure of FD-895 revealed through total synthesis. *Org. Lett.* 2012; 14:5396–5399. [PubMed: 23072504]
16. Sakai Y, Tsujita T, Akiyama T, Yoshida T, Mizukami T, Akinaga S, Horinouchi S, Yoshida M. GEX1 compounds, novel antitumor antibiotics related to herboxidiene, produced by *Streptomyces* sp. II. The effects on cell cycle progression and gene expression. *J. Antibiot. (Tokyo).* 2002; 55:863–872. [PubMed: 12523819]
17. Webb TR, Joyner AS, Potter PM. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. *Drug Discovery Today.* 2013; 18:43–49. [PubMed: 22885522]
18. Venables JP. Aberrant and alternative splicing in cancer. *Cancer Res.* 2004; 64:7647–7654. [PubMed: 15520162]
19. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. *Genes Chromosomes Cancer.* 2005; 42:342–357. [PubMed: 15648050]

20. Bonnal S, Vigevari L, Valcarcel J. The spliceosome as a target of novel antitumour drugs. *Nat. Rev. Drug Discov.* 2012; 11:847–859. [PubMed: 23123942]
21. Ogawa S. Splicing factor mutations in myelodysplasia. *Int. J. Hematol.* 2012; 96:438–442. [PubMed: 23054646]
22. Damm F, Nguyen-Khac F, Fontenay M, Bernard OA. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies. *Leukemia.* 2012; 26:2027–2031. [PubMed: 22484420]
23. Murati A, Brecqueville M, Devillier R, Mozziconacci MJ, Gelsi-Boyer V, Birnbaum D. Myeloid malignancies: mutations, models and management. *BMC Cancer.* 2012; 12:304. [PubMed: 22823977]
24. Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. *Nat. Genet.* 2013; 45:133–135. [PubMed: 23313955]
25. Hubert CG, Bradley RK, Ding Y, Toledo CM, Herman J, Skutt-Kakaria K, Girard EJ, Davison J, Berndt J, Corrin P, Hardcastle J, Basom R, Delrow JJ, Webb T, Pollard SM, Lee J, Olson JM, Paddison PJ. Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. *Genes Dev.* 2013; 27:1032–1045. [PubMed: 23651857]
26. Gao Y, Koide K. Chemical Perturbation of Mcl-1 Pre-mRNA Splicing to Induce Apoptosis in Cancer Cells. *ACS Chem. Biol.* 2013; 8:895–900. [PubMed: 23485022]
27. Osman S, Albert BJ, Wang Y, Li M, Czaicki NL, Koide K. Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464. *Chem. Eur. J.* 2011; 17:895–904. [PubMed: 21226105]
28. Thompson CF, Jamison TF, Jacobsen EN. Convergent Assembly of Chiral Components Prepared by Asymmetric Catalysis. *J. Am. Chem. Soc.* 2000; 122:10482–10483.
29. Horigome M, Motoyoshi H, Watanabe H, Kitahara T. A synthesis of FR901464. *Tetrahedron Lett.* 2001; 42:8207–8210.
30. Thompson CF, Jamison TF, Jacobsen EN. FR901464: total synthesis, proof of structure, and evaluation of synthetic analogues. *J. Am. Chem. Soc.* 2001; 123:9974–9983. [PubMed: 11592876]
31. Albert BJ, Sivaramakrishnan A, Naka T, Koide K. Total synthesis of FR901464, an antitumor agent that regulates the transcription of oncogenes and tumor suppressor genes. *J. Am. Chem. Soc.* 2006; 128:2792–2793. [PubMed: 16506745]
32. Albert BJ, Sivaramakrishnan A, Naka T, Czaicki NL, Koide K. Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue. *J. Am. Chem. Soc.* 2007; 129:2648–2659. [PubMed: 17279752]
33. Lagisetty C, Pourpak A, Jiang Q, Cui X, Goronga T, Morris SW, Webb TR. Antitumor compounds based on a natural product consensus pharmacophore. *J. Med. Chem.* 2008; 51:6220–6224. [PubMed: 18788726]
34. Lagisetty C, Pourpak A, Goronga T, Jiang Q, Cui X, Hyle J, Lahti JM, Morris SW, Webb TR. Synthetic mRNA splicing modulator compounds with in vivo antitumor activity. *J. Med. Chem.* 2009; 52:6979–6990. [PubMed: 19877647]
35. Fan L, Lagisetty C, Edwards CC, Webb TR, Potter PM. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. *ACS Chem. Biol.* 2011; 6:582–589. [PubMed: 21344922]
36. Gundluru MK, Pourpak A, Cui X, Morris SW, Webb TR. Design, synthesis and initial biological evaluation of a novel pladienolide analog scaffold. *Med. Chem. Commun.* 2011; 2:904–908.
37. Jennings L, Murphy GM. Predicting outcome in melanoma: where are we now? *The Br. J. Dermatol.* 2009; 161:496–503.
38. Smith AB 3rd, Dong S, Brennenman JB, Fox RJ. Total synthesis of (+)-sorangicin A. *J. Am. Chem. Soc.* 2009; 131:12109–12111. [PubMed: 19663510]
39. J. Lawrence N, D. Drew M, M. Bushell S. Polymethylhydrosiloxane: a versatile reducing agent for organic synthesis. *J. Chem. Soc., Perkin Transactions 1.* 1999; 0:3381–3391.
40. Goddard-Borger ED, Stick RV. An efficient, inexpensive, and shelf-stable diazotransfer reagent: imidazole-1-sulfonyl azide hydrochloride. *Org. Lett.* 2007; 9:3797–3800. [PubMed: 17713918]

41. Ye H, Liu R, Li D, Liu Y, Yuan H, Guo W, Zhou L, Cao X, Tian H, Shen J, Wang PG. A Safe and Facile Route to Imidazole-1-sulfonyl Azide as a Diazotransfer Reagent. *Org. Lett.* 2012; 15:18–21. [PubMed: 23240732]
42. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF 3rd, Staunton JE, Jin X, Lee MS, Zimmermann GR, Borisy AA. Synergistic drug combinations tend to improve therapeutically relevant selectivity. *Nature Biotechnol.* 2009; 27:659–666. [PubMed: 19581876]
43. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. *Mol. Cancer Ther.* 2008; 7:1851–1863. [PubMed: 18606717]
44. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. *Drug Res. Updat.* 2008; 11:32–50.
45. Liu JY, Park SH, Morisseau C, Hwang SH, Hammock BD, Weiss RH. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. *Mol. Cancer Ther.* 2009; 8:2193–2203. [PubMed: 19671760]
46. Decker M, Arand M, Cronin A. Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. *Arch. Toxicol.* 2009; 83:297–318. [PubMed: 19340413]
47. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Adv. Enzyme Regul.* 1984; 22:27–55. [PubMed: 6382953]
48. Laizure SC, Herring V, Hu Z, Witbrodt K, Parker RB. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? *Pharmacotherapy.* 2013; 33:210–222. [PubMed: 23386599]
49. Fischer N, Goddard-Borger ED, Greiner R, Klapötke TM, Skelton BW, Stierstorfer J. Sensitivities of Some Imidazole-1-sulfonyl Azide Salts. *J. Org. Chem.* 2012; 77:1760–1764. [PubMed: 22283437]

Figure 1. Natural product spliceosome modulators (FR901464,¹⁰ pladienolides,¹¹ herboxidiene,¹² thailanstatins,¹³ and FD-895),¹⁵ along with the semi-synthetic analogs (E7107¹¹ and spliceostatin¹⁰) and a structurally similar totally-synthetic analog class (the meayamycins).²⁷

Figure 2.

The structures of the previously reported compounds sudemycin C1³³ and sudemycin F1³⁵ along with the new preclinical lead compounds sudemycin D1 and D6, which have not previously been disclosed.

Figure 3.

The interactions between (A) compound **2** and BEZ 235 and (B) compound **3** and BEZ 235 result in strong synergism. The IC_{50} curves of drug combinations in the neuroblastoma cell line SK-NA-S are plotted. The combination indexes (CI) shown to the right were calculated at the concentration of drugs required to inhibit 50% of cell proliferation (ED_{50}) in various cell lines. Each experimental condition was carried out in triplicate; error bars represent the SEM. Drug interactions were assessed with the software CalcuSyn 2.1 (Biosoft, Cambridge, UK). The program is based on Chou-Talalay's Combination Index theorem, which renders a quantitative definition of the drugs' interaction defined as the Combination Index (CI).⁴⁷

Figure 4.

Compound **3** inhibits SK-MEL-2 tumor growth in a mouse xenograft model. The arrows indicate a four hour infusion of 50 mg/Kg of either vehicle or compound **3**. Tumor growth was monitored daily 5 times per week. N= 8 for the vehicle group and 9 for the drug treated group. Mice were euthanized when the tumor burden reached the size limit (> 4 cm³). Error bars represent the SEM. Statistical evaluations were assessed using one-tailed *t*-Test, and the symbols above the lines indicate significant differences at: * = *p*<0.05; ¶ = *p*<0.01.

Scheme 1.

A comparison of the original synthetic approach to the sudemycins to the improved route.
(Bt = 2-benzo[d]thiazole)

Scheme 2.

The optimized synthetic approach to key intermediate **5**

i: KOtBu, Me₃SOI, DMSO; ii: polymethylhydrosiloxane, Ti(OiPr)₄; iii: 2-benzthiazoleSH, Ph₃P, diisopropyl diazodicarboxylate, THF; iv: ammonium molybdate, 30% H₂O₂

Scheme 3.

The improved synthesis of sudemycin analogs

i: Borane/THF, 0 °C-rt; ii: 1) TFA, 2) K₂CO₃, 3) Imidazolesulfonyl azide, K₂CO₃; iii: 1) Swern oxidation; 2) Ethyl 2-(triphenylphosphoranylidene)propanoate; iv: DIBAL-H, CH₂Cl₂, -78 °C, v) Pyridine, Dess-Martin periodinane; vi: 5/NaHMDS, THF, -78 °C; vii: 1) Ph₃P, H₂O, 55 °C, 2) 2. DIPEA, HBTU, (*S,Z*)-4-((*TBS*)oxy)pent-2-enoic acid; viii: For carbamates 1) TBAF/THF, 2) 4-Nitrophenylchloroformate/THF; ix: R₁R₂NH/THF; or R "COCl/pyr for esters

Scheme 4.
Synthesis of heteroaryl derivatives

Table 1

The SAR of new ester and carbamate derivatives prepared using previously reported procedures. All activities are based on the mean of three experiments after a 72 h exposure to compound. The cytotoxicity IC₅₀ values are all reported in micromolar units with the standard error of the mean (SEM) was less than ±30% in all cases and were determined as previously reported.³⁴

Chemical structure of compound 19 is shown. It consists of a central 1,3-dioxolane ring. Attached to the ring are a 2-methoxyethyl group, a 2-methyl-2-butyl group, and a 2-methyl-2-butyl group. The structure is labeled 19.

R'	ID	JeKo1	PC3	R'	ID	JeKo1	PC3
-C(CH ₃) ₃	19a	0.34	1.2	N-Methyl-N-t-butylamine	19i	0.78	2.7
n-Butylamine	19b	>1	>10	Morpholine	19j	1.32	7.8
Diethylamine	19c	>1	>10	Piperidine	19k	1.47	7.2
t-Butylamine	19d	>1	7.3	Pyrolidine	19l	0.97	4.6
N-Methyl-N-propylamine	19e	0.61	3.2	Azetidine	19m	0.94	5.2
2-Methoxy ethylamine	19f	>1	>10	-N(CH ₃) ₂	1	0.3	4.4
N-Methyl-N-butylamine	19g	0.69	3.2	-NHCH ₃	19n	0.9	>10
N-Methyl-N-isopropylamine	19h	0.7	3.4	-NH ₂	19o	1.9	>10

Table 2

Comparison of the most active lead compounds

All activities are based on the mean of three experiments after a 72 h exposure to compound. The cytotoxicity IC₅₀ values are all reported in micromolar units. The standard error of the mean (SEM) for cytotoxicity values was less than ±30% in all cases and were determined as previously reported,³⁴ or as described in the Experimental Section (as indicated below). Previously reported compounds are included for comparison and given the appropriate reference. (Protocols for all assays are provided in the Supporting Information section).

Compound	R'	X=	MDM2 Splicing Effects ^a	JeKo1 IC ₅₀ nM	Plasma Stability ^b	Buffer Soluble ^c	Rapid Onset ^d
1³⁵	-N(CH ₃) ₂	O	> 8h	300 ^e	> 5 h	> 10 μM	> 8 h
2	-N(CH ₃) ₂	CH ₂	< 8h	41 ^f	> 5 h	<10 μM	< 8 h
3	-NHCH ₃	CH ₂	< 8h	22 ^f	> 5 h	>10 μM	< 8 h
18a³³	-CH ₃	CH ₂	< 8h	100 ^e	< 5 h	<<10 μM	< 8 h
18b³³	-CH(CH ₃) ₂	CH ₂	< 8h	47 ^e	< 5 h	<<10 μM	< 8 h
18c		CH ₂	ND	170 ^e	ND	>10 μM	ND
18d	-NH ₂	CH ₂	ND	100 ^f	ND	ND	ND
19a³⁴	-CH(CH ₃) ₂	O	ND	220 ^f	< 5 h	>10 μM	> 8 h

ND= Not determined

^aMajor splicing changes observed with 1 μM drug treatment of Rh-18 cells.

^bIn mouse plasma at 37° C as determined by HPLC.

^cSolubility (as determined by HPLC) in PBS.

^dThe time to achieve the majority of the observed 72 h cytotoxicity, based on drug-washout experiments.

^e 72 h cytotoxicity measured using an MTT assay, as previously reported.^{3,4}

^f 72 h cytotoxicity using a Cell Titer Glow assay, as described in the Experimental Section.

Table 3Drug combinations^a showing antagonism or synergy of cytotoxicity of SK-MEL-2 with **compound 2**.^b

First Drug Panel			
Drug	Mechanism of Action	Interaction Type	CI in SK-MEL-2
BEZ235	Dual inhibitor of PI3K and mTOR	Strong synergism	0.21
Bortezomib	Proteasome inhibitor	Antagonism	n.d.
Camptothecin	DNA topoisomerase I inhibitor	Moderate synergism	0.74
Harringtonine	Inhibitor of protein synthesis	Antagonism	n.d.
Imatinib	Tyrosine kinase inhibitor	Antagonism	n.d.
Panobinostat	Broad-spectrum HDAC inhibitor	Moderate synergism	0.76
Silibinin	Multiple Targets	Slight synergism	0.89
Sorafenib	Multikinase inhibitor (inhibits sEH)	Synergism	0.43
SU 9516	Cyclin-dependent kinase-2 inhibitor	Moderate synergism	0.83
Taxol	Microtubule inhibitor	Antagonism	n.d.
Follow-up Drug Panel			
Drug	Mechanism of Action	Interaction Type	CI in SK-MEL-2
PX-866	Irreversible inhibitor of PI3K	Synergism	0.57
Temsirolimus	Inhibitor of mTORC1	Synergism	0.68
AUDA	Inhibitor of sEH	Synergism	n.d.

^aFor the complete table, including the full list of drug that were tested see Supporting Information: Supplementary Tables 2 and 3.^bSee Supporting Information for combination indexes for each drug combination we investigated. The notation n.d. indicates that the CI value was not determined. For some compounds such as AUDA it is not possible to determine a CI because AUDA does not show cytotoxicity as a single agent. Drug interaction was established by combination of various concentrations of compound **2** combined with the indicated drug at a constant concentration.